Baseline injurious violence, recent violent victimization, and medication nonadherence are strong predictors of future injurious violence among individuals with schizophrenia.
The LEAN program demonstrated a 27% improvement in adherence, compared with the 15%-18% range reported for other text message interventions.
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders.
Psychiatrists need to take into account possible drug-drug interactions when prescribing third generation antipsychotics to their patients with schizophrenia.
Valbenazine and tetrabenazine may represent promising options for the treatment of tardive dyskinesia in patients on long-term antipsychotic medications.
Patients with schizophrenia who participated in a telephone intervention problem-solving program were found to have higher rates of medication adherence compared with patients who received routine hospital care for schizophrenia.
Researchers infer from their study’s enrollment that patients with early-phase schizophrenia are willing to try long-acting injectable antipsychotic treatment.
Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…